Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could common bladder medications change how men ejaculate? a study investigates

NCT ID NCT07736560

Knowledge-focused Sponsor: Başakşehir Çam & Sakura City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study looks at whether antimuscarinic drugs used for overactive bladder (OAB) affect how long ejaculation lasts and the time before a man can ejaculate again. Researchers will follow men aged 20 to 50 who are prescribed tolterodine or propiverine for OAB. Participants fill out questionnaires before treatment and again at one and two months. The goal is to see if these bladder medications have any unintended effects on sexual function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
antimuscarinic drugs (tolterodine or propiverine) used for overactive bladder
What this could lead to
If the study finds a link, it could help doctors choose OAB treatments that minimize sexual side effects in men.
What could go wrong
This is a small observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Jan 2026

Finished

Jun 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male patients aged 20-50 presenting to our urology outpatient clinic with overactive bladder symptoms and initiated on antimuscarinic therapy or mirabegron as part of routine clinical care

Ages

20 to 50 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients aged 20-50 years * Diagnosis of overactive bladder (OAB) confirmed clinically * Sexually active * Willing to complete questionnaires at all three time points Exclusion Criteria: * Previous use of antimuscarinic or beta-3 agonist medications * Neurological disorders affecting bladder or sexual function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury) * Prior pelvic surgery or radiotherapy * Use of medications known to affect ejaculatory function (e.g., alpha-blockers, SSRIs, antipsychotics) * Active urinary tract infection * Uncontrolled diabetes mellitus * Unwillingness to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ejaculation abnormal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

overactive bladder Premature Birth premature ejaculation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ejaculation abnormal Overactive bladder (OAB) Premature (early) ejaculation

Contacts and locations

Locations

  • Başakşehir Çam and Sakura City Hospital, Department of Urology

    Istanbul, Istanbul, 34200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.